<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146352</url>
  </required_header>
  <id_info>
    <org_study_id>CP201303</org_study_id>
    <nct_id>NCT02146352</nct_id>
  </id_info>
  <brief_title>AXIOS Stent With Electrocautery Enhanced Delivery System</brief_title>
  <official_title>AXIOS Stent With Electrocautery Enhanced Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xlumena, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xlumena, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent
      with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of
      pancreatic pseudocysts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome Measure 1</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from access site-related bleeding requiring transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome Measure 2</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from access site-related infection requiring intravenous or intramuscular antibiotics and/or extended hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome Measure 3</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from surgery for access-site related perforation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome 4</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from stent migration/dislodgement into the pseudocyst or enteral lumen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome Measure 5</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from tissue injury, defined as ulceration at site of stent implant as observed to persist through 1-week post-stent removal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Adverse Event Outcome Measure 6</measure>
    <time_frame>Index procedure through 1-week post-stent removal</time_frame>
    <description>Freedom from serious adverse event associated with the AXIOS stent and/or (index) implant procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Retention Outcome Measure</measure>
    <time_frame>30 or 60 days post-procedure</time_frame>
    <description>Stent Retention: The stent must remain in place for up to 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumen Patency Outcome Measure</measure>
    <time_frame>30 and/or 60 days post-procedure</time_frame>
    <description>Lumen Patency: The stent lumen must be patent at 30 days and/or 60 days of implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success Outcome Measure 1</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Technical success: Successful placement of the AXIOS stent using the Electrocautery Enhanced AXIOS Delivery System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success Outcome Measure</measure>
    <time_frame>30 or 60 days post-procedure</time_frame>
    <description>Clinical success: At least a 50% decrease in pseudocyst size at 30 days or 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success Outcome Measure 2</measure>
    <time_frame>30 or 60 Day Post-procedure</time_frame>
    <description>Technical Success: Successful removal of AXIOS stent using standard endoscopic snare or forceps</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pancreatic Pseudocyst(s)</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXIOS Stent with Electrocautery Enhanced Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AXIOS Stent with Electrocautery Enhanced Delivery System</intervention_name>
    <description>Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 75 years old, male or female

          2. Eligible for endoscopic intervention

          3. Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage

          4. Symptomatic pancreatic pseudocyst having the following characteristics:

               -  Greater or equal to 6 cm in diameter (based upon the maximum cross-sectional area
                  in the CT scan or transabdominal ultrasound).

               -  Adherent to bowel wall, and

               -  â‰¥70% fluid content

          5. Patient understands the study requirements and the treatment procedures and provides
             written Informed Consent.

          6. Patient is willing to comply with all specified follow-up evaluations, including
             willingness to undergo a pre/post CT imaging study.

        Exclusion Criteria:

          1. The fluid collection to be drained is an immature pseudocyst

          2. The fluid collection to be drained is a cystic neoplasm

          3. The fluid collection to be drained is a pseudoaneurysm

          4. The fluid collection to be drained is a duplication cyst

          5. The fluid collection to be drained is a non-inflammatory fluid collection

          6. There is more than one pseudocyst requiring drainage

          7. Abnormal coagulation:

               -  INR &gt; 1.5 and not correctable

               -  presence of a bleeding disorder

               -  platelets &lt; 50,000/mm3

          8. Altered anatomy that precludes the physician's ability to deliver the stent (decision
             on a case by case basis).

          9. Intervening gastric varices or vessels within a one centimeter radius of the needle
             (visible using endoscopy or endoscopic ultrasound)

         10. Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium),
             silicone or any other materials contacting the patient.

         11. Female of childbearing potential with a positive pregnancy test prior to the procedure
             or intends to become pregnant during the study.

         12. Currently participating in another investigational drug of device study that has not
             completed the primary endpoint or that clinically interferes with the endpoints of
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Edmundowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <results_first_submitted>September 2, 2015</results_first_submitted>
  <results_first_submitted_qc>September 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2015</results_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic pseudocyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Pseudocyst</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30 or 60 Days Post-procedure</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>7 Days Post-stent Removal</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient entered hospice care</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.9" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome Measure 1</title>
        <description>Freedom from access site-related bleeding requiring transfusion</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Entire patient cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome Measure 1</title>
          <description>Freedom from access site-related bleeding requiring transfusion</description>
          <population>Entire patient cohort</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Retention Outcome Measure</title>
        <description>Stent Retention: The stent must remain in place for up to 60 days</description>
        <time_frame>30 or 60 days post-procedure</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Retention Outcome Measure</title>
          <description>Stent Retention: The stent must remain in place for up to 60 days</description>
          <population>Per Protocol Population</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumen Patency Outcome Measure</title>
        <description>Lumen Patency: The stent lumen must be patent at 30 days and/or 60 days of implantation.</description>
        <time_frame>30 and/or 60 days post-procedure</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumen Patency Outcome Measure</title>
          <description>Lumen Patency: The stent lumen must be patent at 30 days and/or 60 days of implantation.</description>
          <population>Per Protocol</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success Outcome Measure 1</title>
        <description>Technical success: Successful placement of the AXIOS stent using the Electrocautery Enhanced AXIOS Delivery System</description>
        <time_frame>Index Procedure</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success Outcome Measure 1</title>
          <description>Technical success: Successful placement of the AXIOS stent using the Electrocautery Enhanced AXIOS Delivery System</description>
          <population>Per Protocol</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success Outcome Measure</title>
        <description>Clinical success: At least a 50% decrease in pseudocyst size at 30 days or 60 days</description>
        <time_frame>30 or 60 days post-procedure</time_frame>
        <population>Entire patient cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success Outcome Measure</title>
          <description>Clinical success: At least a 50% decrease in pseudocyst size at 30 days or 60 days</description>
          <population>Entire patient cohort</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome Measure 2</title>
        <description>Freedom from access site-related infection requiring intravenous or intramuscular antibiotics and/or extended hospitalization</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Entire patient cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome Measure 2</title>
          <description>Freedom from access site-related infection requiring intravenous or intramuscular antibiotics and/or extended hospitalization</description>
          <population>Entire patient cohort</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome Measure 3</title>
        <description>Freedom from surgery for access-site related perforation</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Entire patient cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome Measure 3</title>
          <description>Freedom from surgery for access-site related perforation</description>
          <population>Entire patient cohort</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome 4</title>
        <description>Freedom from stent migration/dislodgement into the pseudocyst or enteral lumen</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Patients for which AXIOS stent migration/dislodgement could be assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome 4</title>
          <description>Freedom from stent migration/dislodgement into the pseudocyst or enteral lumen</description>
          <population>Patients for which AXIOS stent migration/dislodgement could be assessed</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome Measure 5</title>
        <description>Freedom from tissue injury, defined as ulceration at site of stent implant as observed to persist through 1-week post-stent removal</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Patients for which AXIOS stent was removed and tissue at site of stent implant was observed at time of removal</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome Measure 5</title>
          <description>Freedom from tissue injury, defined as ulceration at site of stent implant as observed to persist through 1-week post-stent removal</description>
          <population>Patients for which AXIOS stent was removed and tissue at site of stent implant was observed at time of removal</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Adverse Event Outcome Measure 6</title>
        <description>Freedom from serious adverse event associated with the AXIOS stent and/or (index) implant procedure</description>
        <time_frame>Index procedure through 1-week post-stent removal</time_frame>
        <population>Entire patient cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Adverse Event Outcome Measure 6</title>
          <description>Freedom from serious adverse event associated with the AXIOS stent and/or (index) implant procedure</description>
          <population>Entire patient cohort</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success Outcome Measure 2</title>
        <description>Technical Success: Successful removal of AXIOS stent using standard endoscopic snare or forceps</description>
        <time_frame>30 or 60 Day Post-procedure</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success Outcome Measure 2</title>
          <description>Technical Success: Successful removal of AXIOS stent using standard endoscopic snare or forceps</description>
          <population>Per Protocol</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Index procedure through 1-week post-stent removal</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>AXIOS Stent with Electrocautery Enhanced Delivery System
AXIOS Stent with Electrocautery Enhanced Delivery System: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain/shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding post-AXIOS stent removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatic duct leak</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Spontaneous stent migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness/ dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding post-AXIOS stent removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI must wait 9 months after close of study for Sponsor to present collaborative publication. If Sponsor does not publish within 9 months after close of study, PI may publish institution's results at that time. Sponsor can review results prior to public release and embargo communications on trial results for a period that is more than 60 days but less than or equal to 6 months from the date the PI gets the objection. The Sponsor cannot require changes to the communication nor extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lina Ginnetti</name_or_title>
      <organization>Boston Scientific Corp.</organization>
      <phone>508-683-4512</phone>
      <email>Lina.Ginnetti@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

